within Pharmacolibrary.Drugs.ATC.J;

model J01MA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.00040500000000000003,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.155,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.238,
    k12             = 19.4,
    k21             = 19.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01MA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ciprofloxacin is a second-generation fluoroquinolone antibiotic used to treat a variety of bacterial infections, including urinary tract infections, respiratory tract infections, and skin infections. It is approved for use in adults and in selected pediatric cases for specific infections. Ciprofloxacin is generally administered orally or intravenously.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single oral dose.</p><h4>References</h4><ol><li><p>Junkert, AM, et al., &amp; Pontarolo, R (2024). Pharmacokinetics of oral ciprofloxacin in adult patients: A scoping review. <i>British journal of clinical pharmacology</i> 90(2) 528–547. DOI:<a href=\"https://doi.org/10.1111/bcp.15933\">10.1111/bcp.15933</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37850318/\">https://pubmed.ncbi.nlm.nih.gov/37850318</a></p></li><li><p>Tolentino-Hernández, SJ, et al., &amp; Castañeda-Hernández, G (2020). Oral Ciprofloxacin Pharmacokinetics in Healthy Mexican Volunteers and Other Populations: Is There Interethnic Variability?. <i>Archives of medical research</i> 51(3) 268–277. DOI:<a href=\"https://doi.org/10.1016/j.arcmed.2020.02.008\">10.1016/j.arcmed.2020.02.008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32143939/\">https://pubmed.ncbi.nlm.nih.gov/32143939</a></p></li><li><p>van Rhee, KP, et al., &amp; Knibbe, CAJ (2022). Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. <i>Clinical pharmacokinetics</i> 61(8) 1167–1175. DOI:<a href=\"https://doi.org/10.1007/s40262-022-01130-5\">10.1007/s40262-022-01130-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35641862/\">https://pubmed.ncbi.nlm.nih.gov/35641862</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01MA02;
